Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-25T19:00:35.574Z Has data issue: false hasContentIssue false
  • English
  • Français

122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment

Published online by Cambridge University Press:  15 June 2018

Daniel Weintraub ,
James Norton ,
Bruce Coate ,
Candace Andersson ,
Doral Fredericks  and
Clive Ballard
Daniel Weintraub
Affiliation:
Professor of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
James Norton
Affiliation:
Sr. Dir. Medical Affairs, ACADIA Pharmaceuticals Inc., San Diego, CA
Bruce Coate
Affiliation:
Associate Director Biostatistics, ACADIA Pharmaceuticals Inc., San Diego, CA
Candace Andersson
Affiliation:
Sr. Medical Science Liaison, ACADIA Pharmaceuticals Inc., San Diego, CA
Doral Fredericks
Affiliation:
Vice President Medical Affairs, ACADIA Pharmaceuticals Inc., San Diego, CA
Clive Ballard
Affiliation:
Pro-Vice-Chancellor and Executive Dean, The University of Exeter Medical School, Exeter, UK
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis (PDP) patients withglobal cognitive impairment.

Background

PDP is frequent, distressing, a leading cause of institutionalization, complicates PD management and is linked to increased morbidity, incident dementia and mortality. PIM, a selective serotonin receptor (5-HT2A) inverse agonist/antagonist, is newly FDA-approved for the treatment of hallucinations and delusions associated with PDP.

Methods

In Study 020, a 6-week FDA registration study, 199 patients with baseline Mini-Mental State Examination (MMSE) score ≥21, moderate-severe psychosis, and on stable PD meds, were randomized to PIM (34 mg/day) or placebo (PBO) for 6 weeks. This subgroup analysis evaluates efficacy and safety between two groups: those with MMSE total score ≥21 but <25 (cognitively impaired; equivalent to Montreal Cognitive Assessment [MoCA] score 15-19) and those with score ≥25 (cognitively normal; equivalent to MoCA score 20-30). Safety assessments were performed on the full safety dataset (i.e., three 6-week placebo-controlled studies) including 614 subjects (PIM=382, PBO=231).

Results

Overall, patients in the PIM group experienced a statistically significant improvement in SAPS-PD scores from baseline to Day 43 compared with PBO (-5.79 vs. -2.73; p=0.001). In the subgroup analysis stratifying by baseline MMSE score, the change from baseline to Day 43 compared with PBO in the cognitively-impaired group (N=50) was numerically larger (-7.11 vs. -0.47; p=0.002). In the full safety dataset examining cognitively impaired patients, there were no between-group (PIM vs. PBO) differences in any treatment-emergent adverse event (TEAE) (57.6% vs. 56.1%) or serious TEAE (6.8% vs. 5.3%). The most common TEAEs occurring at ≥5% in either group were fall (7.4% vs.10.5%), confusional state (6.5% vs.1.8%), and orthostatic hypotension (0.0% vs. 8.8%).

Conclusions

In this subgroup analysis of PDP patients, the treatment effect of PIM on SAPS-PD was larger in the cognitively-impaired group, with similar TEAE and serious TEAE rates. These results hold promise for cognitively-impaired patients that will be further elucidated in future studies.

Funding Acknowledgements

Clinical study was funded by ACADIA Pharmaceuticals Inc.

Type
Abstracts
Information
CNS Spectrums , Volume 23 , Issue 1 , February 2018 , pp. 77
Copyright
© Cambridge University Press 2018